Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1976 1
1978 2
1980 1
1981 1
1984 1
1985 1
1986 2
1988 1
1989 5
1990 5
1991 2
1994 3
1995 6
1996 7
1997 6
1998 12
1999 9
2000 13
2001 13
2002 9
2003 12
2004 15
2005 16
2006 17
2007 21
2008 18
2009 9
2010 11
2011 14
2012 12
2013 12
2014 12
2015 12
2016 6
2017 7
2018 3
2019 7
2020 4
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

283 results
Results by year
Filters applied: . Clear all
Page 1
The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial.
Taranto-Montemurro L, Messineo L, Sands SA, Azarbarzin A, Marques M, Edwards BA, Eckert DJ, White DP, Wellman A. Taranto-Montemurro L, et al. Am J Respir Crit Care Med. 2019 May 15;199(10):1267-1276. doi: 10.1164/rccm.201808-1493OC. Am J Respir Crit Care Med. 2019. PMID: 30395486 Free PMC article. Clinical Trial.
Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in peo …
Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic …
A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder.
Leung HY, Yip SK, Cheon C, Liu YS, Lau J, Wong HK, Chung KH. Leung HY, et al. BJU Int. 2002 Sep;90(4):375-80. doi: 10.1046/j.1464-410x.2002.02905.x. BJU Int. 2002. PMID: 12175392 Clinical Trial.
Objective To compare the tolerability and clinical efficacy of tolterodine and oxybutynin in the treatment of Hong Kong Chinese women with an overactive bladder. ...Results The perceived change from baseline VAS was better in the tolterodine than the oxybutynin grou …
Objective To compare the tolerability and clinical efficacy of tolterodine and oxybutynin in the treatment of Hong Kong Chinese women …
Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial.
Yokoyama O, Yamaguchi A, Yoshida M, Yamanishi T, Ishizuka O, Seki N, Takahashi S, Yamaguchi O, Higo N, Minami H, Masegi Y. Yokoyama O, et al. Int J Urol. 2015 Jul;22(7):684-8. doi: 10.1111/iju.12755. Epub 2015 Mar 17. Int J Urol. 2015. PMID: 25782032 Clinical Trial.
OBJECTIVES: To investigate the efficacy of a once-daily oxybutynin patch for nocturia, and its influence on sleep quality in patients with overactive bladder. ...The hours of undisturbed sleep showed significant prolongation by 76.14 min in the oxybutynin patch grou …
OBJECTIVES: To investigate the efficacy of a once-daily oxybutynin patch for nocturia, and its influence on sleep quality in patients …
Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
Homma Y, Paick JS, Lee JG, Kawabe K; Japanese and Korean Tolterodine Study Group. Homma Y, et al. BJU Int. 2003 Nov;92(7):741-7. doi: 10.1046/j.1464-410x.2003.04468.x. BJU Int. 2003. PMID: 14616458 Clinical Trial.
RESULTS: In all, 608 patients were randomized to treatment with tolterodine (240), oxybutynin (246) or placebo (122). More patients prematurely withdrew on oxybutynin (23%) than with tolterodine (10.4%) or placebo (16.4%). ...Patients treated with oxybutynin
RESULTS: In all, 608 patients were randomized to treatment with tolterodine (240), oxybutynin (246) or placebo (122). More patients p …
Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy.
Costa Ada S Jr, Leão LE, Succi JE, Perfeito JA, Filho Castelo A, Rymkiewicz E, Filho Aurelio Marchetti M. Costa Ada S Jr, et al. Clinics (Sao Paulo). 2014 Feb;69(2):101-5. doi: 10.6061/clinics/2014(02)05. Clinics (Sao Paulo). 2014. PMID: 24519200 Free PMC article. Clinical Trial.
RESULTS: Sixteen patients were included in each group (placebo and oxybutynin). There were no significant differences between the groups prior to treatment. ...The outcomes of the transepidermal water loss measurements in the placebo group showed no differences (p=0.95), w …
RESULTS: Sixteen patients were included in each group (placebo and oxybutynin). There were no significant differences between the gro …
Clinical and urodynamic efficacy of oxybutynin and verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, randomized, crossover study.
El-Bahnasawy MS, Shaaban H, Gomha MA, Nabeeh A. El-Bahnasawy MS, et al. Scand J Urol Nephrol. 2008;42(4):344-51. doi: 10.1080/00365590701832726. Scand J Urol Nephrol. 2008. PMID: 19230167 Clinical Trial.
The patients were randomized on entry into one of the two arms of the study: oxybutynin followed by verapamil (n =10); or verapamil followed by oxybutynin (n = 10). ...The number of uninhibited contractions in the last 5 min of filling decreased significantly from 3 …
The patients were randomized on entry into one of the two arms of the study: oxybutynin followed by verapamil (n =10); or verapamil f …
Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial.
Simon JA, Gaines T, LaGuardia KD; Extended-Release Oxybutynin Therapy for VMS Study Group. Simon JA, et al. Menopause. 2016 Nov;23(11):1214-1221. doi: 10.1097/GME.0000000000000773. Menopause. 2016. PMID: 27760081 Clinical Trial.
Mean changes in frequency in the oxybutynin and placebo groups were -9.48 and -4.69 episodes/d, respectively, at week 12. ...Dry mouth was reported by 52.1% of participants given oxybutynin and 5.3% of participants given placebo, leading to discontinuation of oxy
Mean changes in frequency in the oxybutynin and placebo groups were -9.48 and -4.69 episodes/d, respectively, at week 12. ...Dry mout …
Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Reiz JL, Salem P, Darke AC. Reiz JL, et al. J Clin Pharmacol. 2007 Mar;47(3):351-7. doi: 10.1177/0091270006297226. J Clin Pharmacol. 2007. PMID: 17322147 Clinical Trial.
The mean C(max) was lower for controlled-release oxybutynin (5.7 ng/mL) than for immediate-release oxybutynin (7.5 ng/mL) (P = .0051), with a smaller fluctuation in oxybutynin plasma concentration for controlled-release oxybutynin (135.6%) than for imm …
The mean C(max) was lower for controlled-release oxybutynin (5.7 ng/mL) than for immediate-release oxybutynin (7.5 ng/mL) (P = …
Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors.
Montaldo P, Tafuro L, Rea M, Narciso V, Iossa AC, Del Gado R. Montaldo P, et al. BJU Int. 2012 Oct;110(8 Pt B):E381-6. doi: 10.1111/j.1464-410X.2011.10918.x. Epub 2012 Feb 7. BJU Int. 2012. PMID: 22313792 Clinical Trial.
All patients who had experienced failure of treatment with sublingually administered desmopressin alone were given either desmopressin plus 5 mg oxybutynin or desmopressin plus placebo in a randomized, double-blinded trial for 4 weeks. ...The responders to combined oxyb
All patients who had experienced failure of treatment with sublingually administered desmopressin alone were given either desmopressin plus …
Effect of Early Oxybutynin Treatment on Posterior Urethral Valve Outcomes in Infants: A Randomized Controlled Trial.
Abdelhalim A, El-Hefnawy AS, Dawaba ME, Bazeed MA, Hafez AT. Abdelhalim A, et al. J Urol. 2020 Apr;203(4):826-831. doi: 10.1097/JU.0000000000000691. Epub 2019 Dec 10. J Urol. 2020. PMID: 31821098 Clinical Trial.
PURPOSE: We studied the effect of oxybutynin on bladder and upper urinary tract outcomes in infants following posterior urethral valve ablation. ...Oxybutynin was discontinued before toilet training in 5 patients due to facial flushing in 2, bladder and upper tract …
PURPOSE: We studied the effect of oxybutynin on bladder and upper urinary tract outcomes in infants following posterior urethral valv …
283 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page